Unlock Long-Term Wealth with These Two Healthcare Giants
As the new year begins, many people set financial goals, including investing in the stock market. To achieve success, it’s essential to identify companies with the potential to perform well for decades to come. In the healthcare sector, two companies stand out: Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX).
Eli Lilly: A Proven Innovator
Eli Lilly started 2024 strong but faced challenges in the second half of the year. Despite missing analyst estimates, the company’s third-quarter revenue grew by 20% year over year to $11.4 billion. This impressive performance demonstrates Eli Lilly’s innovative capabilities. The company has developed breakthrough medicines, including tirzepatide, a dual GLP-1/GIP treatment for diabetes and weight loss management, and Kisunla, an Alzheimer’s disease treatment.
A Culture of Innovation
Eli Lilly’s long history of dominating the diabetes market is a testament to its internal culture of innovation. The company has created and fostered an environment that encourages innovation, leading to the development of billion-dollar drugs and excellent financial results. With several exciting late-stage pipeline candidates, especially in the weight loss market, Eli Lilly is poised for continued top-line growth well into the 2030s.
Income-Oriented Investors Rejoice
Eli Lilly also offers a solid dividend program, making it an attractive option for income-oriented investors. With $5,000, you can acquire six shares of the company with change left over.
Vertex Pharmaceuticals: A Leader in Rare Genetic Conditions
Vertex Pharmaceuticals is renowned for developing and marketing drugs that treat cystic fibrosis (CF), a rare genetic condition. The company’s revenue and earnings have grown rapidly in the past decade, and its work in CF is no anomaly. Vertex has earned approval for Casgevy, a gene-editing treatment for two rare blood-related conditions, and has exciting pipeline candidates, including suzetrigine, a treatment for acute pain, and inaxaplin, a potential therapy for APOL-1-mediated kidney disease.
A Bright Future Ahead
Vertex’s lineup will undergo a significant transformation in the next five years, and the company is expected to continue performing well beyond that. With $5,000, you can acquire 11 shares of the company.
Don’t Miss Out on Top Stocks
Before investing in Eli Lilly or Vertex Pharmaceuticals, consider the top 10 stocks identified by The Motley Fool Stock Advisor analyst team. These stocks have the potential to produce monster returns in the coming years. Learn more about the latest top 10 list and start building your wealth today.
Leave a Reply